Diadia
Our TechnologyResourcesAboutLoginBook a call

© 2026 Diadia. All rights reserved.

About UsOur TechnologyResearchResources
Privacy Policy
SupportBook a callLogin
Health Privacy Policy
InstagramFacebookLinkedInX (formerly Twitter)
Terms and Conditions
About UsOur TechnologyResearchResources
Privacy Policy
SupportBook a callLogin
Health Privacy Policy
InstagramFacebookLinkedInX (formerly Twitter)
Terms and Conditions

© 2026 Diadia. All rights reserved.

←Transparency Reports

cardiovascular · Mechanism Report

Do ApoB and LDL particle number predict atherosclerotic cardiovascular disease risk even when triglycerides are low?

Higher ApoB or LDL particle number indicates increased ASCVD risk even in people with low triglyceride levels.

SupportedJune 19, 202617 Sources

Reasoning Paths

Each route from condition to outcome carries a support score — the product of its edge weights. Select one to isolate it on the figure.

This is what AI claimed

Apolipoprotein B and LDL particle number reflect the number of atherogenic lipoprotein particles, and higher apoB/LDL particle number is associated with higher atherosclerotic cardiovascular disease risk even when triglycerides are low.

laying out figure…
All 5 paths supported
UnsupportedPlausibleSupported

How to read the figure

Evidence state

  • ●EstablishedStrong, replicated evidence.
  • ◐ModerateEvidence-informed; limited or moderate.
  • ◇PlausibleMechanistically coherent, not established.
  • ✕UnsupportedTested and not supported — link breaks.
  • ?MissingNo evidence either way — untested.

Node shapes

  • BiomarkerA measurable state — a lab value, hormone, or genetic factor.
  • ProcessA biological process, pathway, or mechanism step.
  • ConditionA condition, exposure, intervention, or symptom.
  • OutcomeThe endpoint the claim leads to.

Executive summary

The claim states that ApoB and LDL-P quantify the number of atherogenic lipoprotein particles and that particle count, not cholesterol mass, drives plaque formation. Because each atherogenic particle contains one ApoB molecule, elevated ApoB/LDL-P can reveal high particle burden and residual ASCVD risk when triglycerides and LDL-C appear low due to cholesterol-depleted, small dense particles.

Verified conclusion

While traditional lipid panels focus on the cholesterol mass within particles (LDL-C), modern cardiovascular research emphasizes that the concentration of the particles themselves is the primary driver of arterial plaque formation.

Quantitative precision of ApoB and LDL-P

The accuracy of Apolipoprotein B (ApoB) and LDL particle number (LDL-P) as markers of atherogenic burden is rooted in a fundamental biological principle: stoichiometry.

  • 1:1 Stoichiometry: Every atherogenic lipoprotein particle—including very-low-density lipoprotein (VLDL), intermediate-density lipoprotein (IDL), low-density lipoprotein (LDL), and lipoprotein(a)—contains exactly one molecule of Apolipoprotein B.
  • Direct Particle Counting: Measuring ApoB concentration provides a precise count of the total number of circulating atherogenic particles. While LDL-P specifically counts LDL particles (typically via NMR spectroscopy), both metrics are highly correlated (r > 0.8–0.9) and offer a more granular view of risk than cholesterol mass alone.

ASCVD risk and the "low triglyceride" context

High particle numbers remain a potent predictor of atherosclerotic cardiovascular disease (ASCVD) even when triglyceride (TG) levels are low (<150 mg/dL).

  • Addressing Discordance: In many individuals, particularly those with low TG, there is a "discordance" where LDL-C appears low or normal, but ApoB/LDL-P remains high. This often happens when particles are small, dense, and depleted of cholesterol.
  • Clinical Risk Significance: Evidence from the UK Biobank and CARDIA studies shows that when ApoB is high relative to LDL-C, the hazard ratio for major adverse cardiovascular events (MACE) remains elevated (HR ~1.15–1.2).
  • Pathogenic Mechanism: Because every ApoB-containing particle is capable of penetrating the arterial wall and becoming trapped, the risk is determined by the total number of particles rather than the amount of cholesterol they carry.

Bottom line

ApoB and LDL-P are highly accurate measures of atherogenic particle concentration. Elevated levels indicate significant cardiovascular risk even when triglycerides and LDL-C appear optimal, as they capture the residual risk associated with a high number of cholesterol-depleted particles.

References

  1. Lipoprotein(a) and risk-weighted apolipoprotein B: a novel metric for atherogenic risk — lipidworld.biomedcentral.com ↗
  2. Is Apolipoprotein B and Small, Dense low density lipoprotein a better marker of cardiovascular risk? — ssjournals.com ↗
  3. Apolipoprotein B and Cardiovascular Disease: Biomarker and Potential Therapeutic Target — pmc.ncbi.nlm.nih.gov ↗
  4. Excess Apolipoprotein B and Cardiovascular Risk in Women and Men. — linkinghub.elsevier.com ↗
  5. Effects of apolipoprotein B on lifespan and risks of major diseases including type 2 diabetes: a mendelian randomisation analysis using outcomes in first-degree relatives — linkinghub.elsevier.com ↗
  6. Abstract P180: Navigating Lipid Discrepancies: Implications for Cardiovascular Risk With LDL, Non-HDL, LDL-P, and ApoB — ahajournals.org ↗
  7. ApoB, LDL-C, and non-HDL-C as markers of cardiovascular risk. — linkinghub.elsevier.com ↗
  8. Remnant Cholesterol, Not LDL Cholesterol, Explains Peripheral Artery Disease Risk Conferred by apoB: A Cohort Study — ahajournals.org ↗
  9. Apolipoprotein B outperforms low density lipoprotein particle number as a marker of cardiovascular risk in the UK Biobank. — academic.oup.com ↗
  10. Apolipoprotein B in the Risk Assessment, Diagnosis, and Treatment of Cardiometabolic Diseases — fortunejournals.com ↗
  11. Relationship between plasma apolipoprotein B concentrations and LDL particle number — dovepress.com ↗
  12. Abstract 4362647: Impact of LDL-C and Apolipoprotein B Discordance and Associated Lipoprotein Particle Changes on Major Adverse Cardiovascular Events in a Large Primary Prevention Cohort — ahajournals.org ↗
  13. Association of Apolipoprotein B-Containing Lipoproteins and Risk of Myocardial Infarction in Individuals With and Without Atherosclerosis: Distinguishing Between Particle Concentration, Type, and Content. — jamanetwork.com ↗
  14. Discordance among apoB, non–high-density lipoprotein cholesterol, and triglycerides: implications for cardiovascular prevention — pmc.ncbi.nlm.nih.gov ↗
  15. Discordance between serum cholesterol concentration and atherogenic lipoprotein particle number in people with metabolic disease: A systematic review — dom-pubs.pericles-prod.literatumonline.com ↗
  16. Role of apolipoprotein B in the clinical management of cardiovascular risk in adults: An expert clinical consensus from the national lipid association. — linkinghub.elsevier.com ↗
  17. Apolipoprotein B in cardiovascular risk assessment — pmc.ncbi.nlm.nih.gov ↗

See a full patient report verified like this

Book a walkthrough

Related Claims

Plausible10 sourcesAre F2-isoprostanes biomarkers of lipid peroxidation and does oxidized LDL contribute to atherosclerosis?→Plausible10 sourcesDo hs-CRP, Lp-PLA2, and myeloperoxidase reflect different cardiovascular risk signals?→